Table 2.

Spearman’s rank correlations between biomarker concentration differences and doxorubicin dose intensity measures

	Doxo C max (of corresponding sampling period)	Doxo AUC (of corresponding sampling period)	Doxo AUC (sum of all doxo administrations from first to second sampling period)	Doxo dose/BSA (sum of all doxo administrations from first to second sampling period)
NT-proANP (sample B)–NT-proANP (sample A)	−0.276 (p = 0.009)	−0.037 (p = 0.722)
NT-proANP (sample D)–NT-proANP (sample C)	−0.207 (p = 0.052)	−0.310 (p = 0.767)
BNP (sample B)–BNP (sample A)	−0.382 (p < 0.001)	−0.204 (p = 0.057)
BNP (sample D)–BNP (sample C)	−0.306 (p = 0.004)	−0.066 (p = 0.536)
NT-proBNP (sample B)–NT-proBNP (sample A)	−0.219 (p = 0.041)	−0.079 (p = 0.454)
NT-proBNP (sample D)–NT-proBNP (sample C)	−0.214 (p = 0.046)	0.079 (p = 0.452)
cTnT (sample E)–cTnT (sample A)			0.104 (p = 0.348)	0.181 (p = 0.1)
cTnI (sample E)–cTnI (sample A)			0.233 (p = 0.048)	0.262 (p = 0.025)